Barclays PLC Raises Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Barclays PLC grew its stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 111.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,261 shares of the company’s stock after acquiring an additional 56,474 shares during the period. Barclays PLC owned 0.15% of ORIC Pharmaceuticals worth $1,100,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Victory Capital Management Inc. lifted its holdings in shares of ORIC Pharmaceuticals by 4.1% in the 3rd quarter. Victory Capital Management Inc. now owns 99,750 shares of the company’s stock worth $1,022,000 after buying an additional 3,900 shares during the period. Profund Advisors LLC lifted its stake in ORIC Pharmaceuticals by 23.6% in the second quarter. Profund Advisors LLC now owns 21,861 shares of the company’s stock worth $155,000 after acquiring an additional 4,175 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of ORIC Pharmaceuticals by 71.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,568 shares of the company’s stock valued at $139,000 after purchasing an additional 5,646 shares in the last quarter. Quest Partners LLC lifted its position in shares of ORIC Pharmaceuticals by 253.2% in the 2nd quarter. Quest Partners LLC now owns 10,378 shares of the company’s stock worth $73,000 after purchasing an additional 7,440 shares during the period. Finally, Verition Fund Management LLC boosted its stake in shares of ORIC Pharmaceuticals by 25.6% during the third quarter. Verition Fund Management LLC now owns 42,980 shares of the company’s stock valued at $441,000 after purchasing an additional 8,752 shares in the last quarter. 95.05% of the stock is owned by hedge funds and other institutional investors.

ORIC Pharmaceuticals Stock Performance

Shares of NASDAQ ORIC opened at $8.60 on Tuesday. The firm has a market cap of $606.88 million, a PE ratio of -4.78 and a beta of 1.18. ORIC Pharmaceuticals, Inc. has a one year low of $6.33 and a one year high of $16.65. The firm has a fifty day moving average of $9.00 and a 200 day moving average of $9.43.

ORIC Pharmaceuticals (NASDAQ:ORIC) last announced its earnings results on Tuesday, November 12th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.01). On average, equities analysts predict that ORIC Pharmaceuticals, Inc. will post -1.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on ORIC shares. HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of ORIC Pharmaceuticals in a research report on Monday. Wedbush reissued an “outperform” rating and set a $20.00 price target on shares of ORIC Pharmaceuticals in a research report on Monday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ORIC Pharmaceuticals in a research report on Monday, September 23rd. Finally, Wells Fargo & Company assumed coverage on shares of ORIC Pharmaceuticals in a research report on Thursday, October 31st. They set an “overweight” rating and a $20.00 target price for the company. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $18.29.

Insider Transactions at ORIC Pharmaceuticals

In other ORIC Pharmaceuticals news, insider Pratik S. Multani sold 8,850 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $8.28, for a total value of $73,278.00. Following the transaction, the insider now directly owns 46,765 shares in the company, valued at $387,214.20. The trade was a 15.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Dominic Piscitelli sold 8,851 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $8.28, for a total transaction of $73,286.28. Following the sale, the chief financial officer now owns 106,764 shares of the company’s stock, valued at $884,005.92. This represents a 7.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 42,361 shares of company stock worth $350,749 in the last ninety days. Insiders own 5.55% of the company’s stock.

ORIC Pharmaceuticals Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.